Compare IDEXX Laboratories, Inc. (IDXX) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? IDEXX Laboratories, Inc. trades at $567.52 (market cap $44.95B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.75. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | NVDL | |
|---|---|---|
Market Cap | $44.95B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $766.68 | $43.02 |
52-Week Low | $526.44 | $21.76 |
Enterprise Value | $45.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $566.93, down 3.36% on the day, with a neutral technical signal and strong support near $565. The company reported robust Q2 2026 earnings, beating EPS estimates with $4.27 versus $3.94 expected, and raised full-year EPS guidance to $14.69–14.94. Revenue grew 10% year-over-year, driven by companion animal diagnostics, while profitability remains high with a net margin of 25.03% in 2025. Analyst consensus is bullish with a $683.33 price target, though valuation multiples like P/E of 40.1 suggest a premium.
Outlook is positive due to consistent earnings beats, international expansion, and innovation in veterinary diagnostics, but risks include elevated valuation sensitivity, competitive pressures, and reliance on pet healthcare spending. The stock offers growth potential if execution continues, yet investors should weigh high multiples against sustained profitability trends.
NVDL trades at $36.40, up 6.09% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent stock splits on June 25-26, 2026, adjusted share structure, while leveraged exposure to NVIDIA drives volatility. Support sits at $35-$36, resistance at $37-$38.
Outlook hinges on NVIDIA's AI leadership and late-August earnings, offering amplified gains but high risk from daily leverage reset. Key risks include NVIDIA's volatility, ETF decay, and market sentiment shifts. Investors must weigh leveraged upside against potential sharp declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
